Prevalence of Host and Viral Genotypes in Patients withChronic Hepatitis C and Chronic Hepatitis B Infection in India

Gilead Sciences Inc0 个研究点目标入组 1,000 人开始时间: 待定最近更新: 2021年11月24日

试验速览

暂无简介。

•ï?? Willing and able to provide written informed consent
•ï?? Male or female, age >=18 years old
•ï?? Willing and able to comply with the visit procedures
•ï?? Prior diagnosis of chronic HCV infection or chronic HBV infection; a history of chronic HCV or HBV infection provided by a subject or a subjectâ??s health provider is sufficient; documentation not required At each center, no more than 40% of the patients with previously known chronic HBV enrolled in the study may be inactive carriers (i.e., HBsAg positive with HBV DNA < 2000 IU/ml).

•ï?? History of difficulty with blood collection and/or poor
•venous access for the purposes of phlebotomy.
•ï?? History of bleeding disorder
•ï?? Blood loss requiring transfusion or 3 g/dL decrease in
•hemoglobin within 4 days of the visit
•ï?? Knowingly co-infected with HCV/HBV or with HIV
•ï?? Currently undergoing therapy for chronic hepatitis C or chronic hepatitis B. For the purposes of the study, the last dose of prior HCV or HBV therapy (if applicable) must have been administered 30 days prior to the study visit date for this trial.
•ï?? Currently receiving treatment with any other investigational agent or device. For the purposes of the study, the last dose of any investigational agent or utilization of any investigational device must have been administered 30 days prior to the study visit date for this trial.
•ï?? Enrolled in another clinical study evaluating a treatment or procedure. Subjects may be enrolled in another clinical study evaluating a treatment or procedure >=24 hours following the completion of the study visit assessments and procedures for this trial.

发起方